Benzimidazole carboxylic acids acting as glucagon-like peptide 1 receptor (GLP-1R) agonists have been reported in a Terns Pharmaceuticals Inc. patent as potentially useful for the treatment of diabetes, obesity and liver diseases.
Research at Incyte Corp. has led to the development of hetero-tricyclic compounds acting as GTPase KRAS (mutant) inhibitors and thus reported to be useful for the treatment of cancer, inflammatory and immunological disorders.
Lomond Therapeutics Inc. has prepared and tested compounds having N-arylpyrimidin-2-amine derivatives and acting as protein kinase inhibitors, particularly mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1). As such, they are reported to be useful for the treatment of autoimmune diseases, sepsis, neurodegeneration, male infertility, vascular and inflammatory disorders, cancer and viral infections.
Clevudine derivatives and its phosphoramidates have been detailed in an Emory University patent as potentially useful for the treatment of hepatitis B virus (HBV) infection.
Long Island University and Mount Sinai School of Medicine have jointly developed intermediate conductance KCa3.1 (IKCa1) channel blockers reported to be useful for the treatment of renal disorders.
Recent Vanderbilt University patents describe metabotropic glutamate mGlu5 receptor negative allosteric modulators reported to be useful for the treatment of amyotrophic lateral sclerosis, Angelman syndrome, anxiety disorder, autism spectrum disorders, substance abuse and dependence, Alzheimer’s disease, diabetes and obesity, among others.
Medshine Discovery Inc. has prepared octahydropyrazinodiazanaphthyridine dione compounds acting as GTPase KRAS inhibitors reported to be useful for the treatment of cancer.
Acerand Therapeutics (Hong Kong) Ltd. has patented pyrimidine-containing dihydropyrazolone derivatives acting as Wee1-like protein kinase (Wee1) inhibitors and reported to be useful for the treatment of cancer.
RSS